Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says

Executive Summary

Generic applications continue to be tripped up by failing to adhere to other well-known standards such as paying user fees, US agency says.

Advertisement

Related Content

New US FDA Generics Director Praises Industry, Encourages Partnerships
ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says
ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
ANDA Refuse-to-Receive Challenges Become More Common – And More Successful

Topics

Advertisement
UsernamePublicRestriction

Register

PS122139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel